Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: John Bloxom who wrote (1717)	2/9/1999 8:48:00 AM
From: Biomaven	Read Replies (2) \| Respond to of 10280

John, Chiroscience is also developing a single isomer Ritalin. I've never been able to figure out the conflicting patent claims between them. Here's something from the Chiro web site www.chiroscience.com : Background Chiroscience R&D in collaboration with Medeva PLC is developing this single enantiomeric version of methylphenidate. The racemic drug is the major therapeutic used for the treatment of attention deficit hyperactivity disorder (ADHD) in children, and Medeva are the world's major supplier. ADHD is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to sustain attention or focus on a task and some patients may be unable to control impulsive behavior. Status In the Phase I study, a single escalating dose crossover study in 12 healthy adults, we confirmed the tolerability of D2785 and demonstrated dosing advantages over the existing racemic compound. Medeva are now undertaking full clinical development of D2785. Formulation development and technology transfer are leading to pivotal regulatory trials in the USA, with first filing anticipated late in 1999. Medeva are also financing the scale-up of the novel production process for D2785, developed by Chiroscience R&D, in preparation for full scale manufacturing. Once launched, Chiroscience R&D anticipates receiving a significant revenue stream from royalties on all sales of D2785 worldwide: the current market for the racemic drug exceeds $300m, mainly in the USA. This product is protected by an estate of nine internationally filed formulation, use, process and composition of matter patents, seven of which have been published, so that the Chiroscience R&D/Medeva collaboration is in an excellent competitive position.